Integration of High Throughput ‘Omic Platforms into Antibody Discovery

Video   Dec 23, 2016

 

From antibodies to vaccines to T cells, cancer immunotherapy is extending patient lives. Targeted therapies using immune cell receptors can be targeted to either cancer or immune cells. In pursuit of lead structures, ‘omic technologies are revolutionizing the discovery and development of novel biological lead structures. However, ‘omic platforms are first and foremost data generation instruments that require careful integration into workflows. Here, we demonstrate how we have applied next-generation sequencing, big data, biostatistics, and computational immunology to the discovery and development of novel lead structures.

 
 
 
 

Recommended Videos

Science Talk: Antibody Neutralizes Two Deadliest Ebola Virus Species

Video

Jonathan Lai, Ph.D., and colleagues have engineered the first antibodies that can potentially neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever.

WATCH NOW

Zika Virus: Researchers Develop New Model to Help Test Vaccines and Treatments

Video

An alternative animal model that mimics key features of the Zika virus infection, including its lingering presence in bodily fluids, has been developed at Texas Biomedical Research Institute in San Antonio, to help develop vaccines and treatments.

WATCH NOW

Immunotherapy: Cancer Assassin

Video

Research at the University of Southampton is looking at how immunotherapy can enable the body’s immune system to recognise and kill cancer cells.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE